Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone610-225-6800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.45 billion
Profitability
Miscellaneous
Employees15,200
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Teleflex (NYSE:TFX) Frequently Asked Questions
What is Teleflex's stock symbol?
Teleflex trades on the New York Stock Exchange (NYSE) under the ticker symbol "TFX."
How often does Teleflex pay dividends? What is the dividend yield for Teleflex?
Teleflex announced a quarterly dividend on Thursday, August 1st. Stockholders of record on Thursday, August 15th will be given a dividend of $0.34 per share on Monday, September 16th. This represents a $1.36 annualized dividend and a dividend yield of 0.41%. The ex-dividend date is Wednesday, August 14th. View Teleflex's Dividend History.
How were Teleflex's earnings last quarter?
Teleflex Incorporated (NYSE:TFX) released its quarterly earnings data on Thursday, August, 1st. The medical technology company reported $2.66 EPS for the quarter, topping the Zacks' consensus estimate of $2.59 by $0.07. The medical technology company had revenue of $652.50 million for the quarter, compared to the consensus estimate of $637.06 million. Teleflex had a return on equity of 18.57% and a net margin of 10.78%. The firm's quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.47 earnings per share. View Teleflex's Earnings History.
When is Teleflex's next earnings date?
What guidance has Teleflex issued on next quarter's earnings?
Teleflex issued an update on its FY19 earnings guidance on Thursday, August, 1st. The company provided EPS guidance of $10.90-11.10 for the period, compared to the Thomson Reuters consensus EPS estimate of $11.04. The company issued revenue guidance of +6.0-6.5% to ~$2.6 billion, compared to the consensus revenue estimate of $2.59 billion.
What price target have analysts set for TFX?
10 analysts have issued 12 month target prices for Teleflex's stock. Their predictions range from $310.00 to $420.00. On average, they anticipate Teleflex's stock price to reach $378.10 in the next twelve months. This suggests a possible upside of 14.9% from the stock's current price. View Analyst Price Targets for Teleflex.
What is the consensus analysts' recommendation for Teleflex?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teleflex in the last year. There are currently 1 hold rating, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Teleflex.
What are Wall Street analysts saying about Teleflex stock?
Here are some recent quotes from research analysts about Teleflex stock:
- 1. According to Zacks Investment Research, "Teleflex exited the first quarter of 2019 on a solid note with better-than-expected earnings and revenues figures. The promising performance was driven by strong growth in Interventional Urology, Interventional Access and OEM. Geographically, Asia and Americas both registered strong constant currency revenue growth. We currently look forward to Urolift’s impending limited launch Japan following its Shonn approval. This apart, Teleflex announced a major reimbursement milestone for Urolift of receiving a positive coverage decision from health insurer Humana. Vascular solutions synergy is progressing well. Management also seems to be confident about its recently completed Essential Medical buyout. On the flip side, escalating operating expenses are putting pressure on the bottom line. Tough competition and pricing pressure also weigh on the stock. Overall, in the past three months, shares of Teleflex consistently outperformed its industry." (5/14/2019)
- 2. Needham & Company LLC analysts commented, "TFX is changing its product categories and segments and we have updated our revenue model to reflect the changes. While we are maintaining our prior total revenue and EPS estimates, we are publishing our estimates for the new product categories and segments. We view RePlas as potential sources of upside to TFX’s 2019 guidance and we reiterate our Strong Buy rating." (3/26/2019)
Has Teleflex been receiving favorable news coverage?
Media stories about TFX stock have trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Teleflex earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave headlines about the medical technology company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Teleflex.
Who are some of Teleflex's key competitors?
Some companies that are related to Teleflex include Boston Scientific (BSX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ResMed (RMD), DexCom (DXCM), ABIOMED (ABMD), Insulet (PODD), Novocure (NVCR), Hill-Rom (HRC), Haemonetics (HAE), Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED), Cantel Medical (CMD) and Tandem Diabetes Care (TNDM).
What other stocks do shareholders of Teleflex own?
Who are Teleflex's key executives?
Teleflex's management team includes the folowing people:
- Mr. Liam J. Kelly, Pres, CEO & Director (Age 52)
- Mr. Thomas E. Powell, Exec. VP & CFO (Age 57)
- Mr. James J. Leyden, VP, Gen. Counsel & Sec. (Age 52)
- Mr. John R. Deren, VP & Chief Accounting Officer
- Mr. Timothy F. Duffy, Chief Information Officer & VP
Who are Teleflex's major shareholders?
Teleflex's stock is owned by many different of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (12.98%), Vanguard Group Inc. (10.75%), BlackRock Inc. (8.75%), BlackRock Inc. (8.75%), Atlanta Capital Management Co. L L C (5.23%) and Janus Henderson Group PLC (2.08%). Company insiders that own Teleflex stock include Andrew A Krakauer, Benson Smith, Cameron P Hicks, George Babich Jr, John C Heinmiller, John Deren, Karen Boylan, Stephen K MD Klasko, Stuart A Randle, Thomas Anthony Kennedy and Thomas E Powell. View Institutional Ownership Trends for Teleflex.
Which major investors are selling Teleflex stock?
TFX stock was sold by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Jennison Associates LLC, Jennison Associates LLC, First Trust Advisors LP, Citadel Advisors LLC, Bank of New York Mellon Corp, Westwood Holdings Group Inc. and Parnassus Investments CA. Company insiders that have sold Teleflex company stock in the last year include Benson Smith, Cameron P Hicks, John Deren, Karen Boylan, Stephen K MD Klasko, Stuart A Randle, Thomas Anthony Kennedy and Thomas E Powell. View Insider Buying and Selling for Teleflex.
Which major investors are buying Teleflex stock?
TFX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., BlackRock Inc., Invesco Ltd., Marshall Wace LLP, Point72 Asset Management L.P., Nuveen Asset Management LLC, Vanguard Group Inc. and Natixis. Company insiders that have bought Teleflex stock in the last two years include Andrew A Krakauer and John C Heinmiller. View Insider Buying and Selling for Teleflex.
How do I buy shares of Teleflex?
Shares of TFX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Teleflex's stock price today?
One share of TFX stock can currently be purchased for approximately $329.13.
How big of a company is Teleflex?
Teleflex has a market capitalization of $15.22 billion and generates $2.45 billion in revenue each year. The medical technology company earns $200.80 million in net income (profit) each year or $9.90 on an earnings per share basis. Teleflex employs 15,200 workers across the globe.View Additional Information About Teleflex.
What is Teleflex's official website?
How can I contact Teleflex?
Teleflex's mailing address is 550 E SWEDESFORD RD, WAYNE PA, 19087. The medical technology company can be reached via phone at 610-225-6800 or via email at [email protected]
MarketBeat Community Rating for Teleflex (NYSE TFX)
MarketBeat's community ratings are surveys of what our community members think about Teleflex and other stocks. Vote "Outperform" if you believe TFX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TFX will underperform the S&P 500 over the long term. You may vote once every thirty days.
